缬沙坦联合赖诺普利治疗原发性高血压的疗效观察

Clinical observation of valsartan combined with lisinopril in treatment of primary hypertension

目的探讨缬沙坦胶囊联合赖诺普利胶囊治疗原发性高血压的临床疗效。方法选取2016年3月—2017年2月如皋市中医院收治的原发性高血压患者142例为研究对象,采取随机分组法将所有患者分为对照组和治疗组,每组各71例。对照组晨起空腹口服赖诺普利胶囊,10 mg/次,1次/d。治疗组在对照组的基础上晨起口服缬沙坦胶囊,80 mg/次,1次/d。两组患者均连续治疗8周。观察两组的临床疗效,比较两组的血压情况。结果治疗后,对照组和治疗组总有效率分别为87.32%、97.18%,两组比较差异具有统计学意义(P<0.05)。治疗4、6、8周后,两组收缩压(SBP)和舒张压(DBP)均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论缬沙坦胶囊联合赖诺普利胶囊治疗原发性高血压具有较好的疗效,能显著降低SBP和DBP,安全性较好,具有一定的临床推广应用价值。

Objective To observe the clinical effect of Valsartan Capsules combined with Lisinopril Capsules in treatment of primary hypertension. Methods Patients （142 cases） with primary hypertension in Rugao Hospital of Traditional Chinese Medicine from March 2016 to February 2017 were randomly divided into control and treatment groups, and each group had 71 cases. Patients in the control group were po administered with Lisinopril Capsules at the morning empty stomach, 10 mg/time, once daily. Patients in the treatment group were po administered with Valsartan Capsules at the morning empty stomach on the basis of the control group, 80 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the blood pressure in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 87.32% and 97.18%, respectively, and there was difference between two groups （P 〈 0.05）. After treatment, the levels of SBP and DBP in two groups were significantly decreased, and the difference was statistically significant in the same group （P 〈 0.05）. And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Valsartan Capsules combined with Lisinopril Capsules has clinical curative effect in treatment of primary hypertension, can significantly decrease the level of SBP and DBP, with good safety, which has a certain clinical application value.